Olodaterol and vilanterol detection in sport drug testing

被引：2

作者：

Chundela, Zdenek ^{[1
]}

Grosse, Joachim ^{[1
]}

机构：

[1] Inst Doping Anal & Sport Biochem Dresden, D-01731 Kreischa, Germany

来源：

DRUG TESTING AND ANALYSIS | 2015年 / 7卷 / 11-12期

关键词：

olodaterol; vilanterol; ss(2)-agonists; sport drug testing; BETA(2)-ADRENOCEPTOR AGONIST;

D O I：

10.1002/dta.1918

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

The possibility of the detection of olodaterol and vilanterol, two novel (2)-agonists, in human urine for the purpose of sport drug testing was investigated. Compounds of interest were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) employing methods commonly used in the World Anti-Doping Agency (WADA) accredited laboratories. For both substances, the respective parent compound was found to be a suitable target analyte for monitoring therapeutic dose administration. Copyright (c) 2015 John Wiley & Sons, Ltd.

引用

页码：980 / 982

页数：3

共 50 条

[21] Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study
Gregory J. Feldman
Ana R. Sousa
David A. Lipson
Lee Tombs
Neil Barnes
John H. Riley
Sadhana Patel
Ian Naya
Chris Compton
Bernardino Alcázar Navarrete
Advances in Therapy, 2017, 34 : 2518 - 2533
[22] Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI)
Palli, Swetha
Elliott, Caitlin
Xie, Bin
Chastek, Benjamin
Bengston, Lindsay
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[23] Resource Use, Costs and Clinical Outcomes among COPD Patients Who Initiate Therapy with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol
Sethi, S.
Palli, S.
Bengtson, L.
Buysman, E.
Clark, B.
Sargent, A.
Shaikh, A.
Ferguson, G. T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[24] TESTING TIME FOR SPORT
LOCKWOOD, C
NEW SCIENTIST, 1992, 135 (1831) : 47 - 48
[25] COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS TIOTROPIUM/OLODATEROL (TIO/OLO) IN PATIENTS WITH COPD: UNITED KINGDOM PAYER PERSPECTIVE
Kendall, R.
Martin, A.
Shah, D.
Noorduyn, S. G.
Dasari, P.
Risebrough, N.
Ismaila, A.
VALUE IN HEALTH, 2023, 26 (12) : S191 - S191
[26] Drug Repurposing of Olodaterol, Formoterol, Indacaterol and Forskolin for Congenital Myasthenic Syndromes
Ho, Kelly
Spendiff, Sally
Myers, Stephanie
Gray, Mark
Lochmuller, Hanns
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2025, 392 (03):
[27] Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment-Naive Patients with COPD in the US
Shaikh, Asif
Ritz, John
Casciano, Julian
Palli, Swetha R.
Clark, Brendan
Dotiwala, Zenobia
Quint, Jennifer K.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2025, 20 : 335 - 348
[28] Resource Use, Costs and Clinical Outcomes Among COPD Patients Initiated on Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
Sethi, S.
Clark, B.
Bengtson, L.
Buysman, E.
Palli, S.
Sargent, A.
Shaikh, A.
Ferguson, G. T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[29] Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol
Sethi, Sanjay
Palli, Swetha R.
Bengtson, Lindsay G. S.
Buysman, Erin K.
Clark, Brendan
Sargent, Andrew
Shaikh, Asif
Ferguson, Gary T.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (07): : 791 - 806
[30] Evaluation of Rescue Medication Use and Medication Adherence in Patients Initiating Umeclidinium/Vilanterol or Tiotropium/Olodaterol Within a Large US Health Insurer Database
Moretz, C.
Bengtson, L. G. S.
Koep, E.
Sharpsten, L.
Le, L.
Tong, J.
Hahn, B.
Stanford, R.
Asmus, M. J.
Ray, R.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199

← 1 2 3 4 5 →